{"product":"fda-untitled-letter-bodies","name":"FDA Untitled Letters (CDER OPDP + CBER promo)","free":true,"note":"Full catalog: count + id + firm + date + product + official URL. Not /warning-letters. Free index/search (?q=, optional before/date) stays free and includes id, the ?id= URL ($0.02), and the page cursor ($0.05). GET /untitled-letters?id= is one official text GET ?id= ($0.02). Plain paid GET /untitled-letters is the newest 10 official texts; older chunk if they ask (?before=<id or date>, another $0.05); newer than a watermark ?since=<ISO timestamp or official catalog id> ($0.05; empty new set is 304 or recordCount 0).","license":"17 USC 105","payTo":"0xf59621FC406D266e18f314Ae18eF0a33b8401004","network":"base","asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","amountAtomic":"50000","priceUsdc":"0.05","fetchedAt":"2026-09-05T02:04:26.441Z","asOf":"2026-08-21","cardCount":120,"cards":[{"id":"alar-pharmaceuticals-inc-194514","firm":"Alar Pharmaceuticals Inc.","date":"2026-08-21","product":"ALA-3000 (ketamine pamoate) injection","sourceUrl":"https://www.fda.gov/media/194514/download","publishedAt":"2026-08-21","page":1,"before":null,"paidUrl":"/untitled-letters?id=alar-pharmaceuticals-inc-194514"},{"id":"sanofi-vaccines-us-inc-193721","firm":"Sanofi Vaccines US Inc.","date":"2026-07-15","product":"BEYFORTUS® (nirsevimab-alip) injection, for intramuscular use","sourceUrl":"https://www.fda.gov/media/193721/download","publishedAt":"2026-07-15","page":1,"before":null,"paidUrl":"/untitled-letters?id=sanofi-vaccines-us-inc-193721"},{"id":"viatris-specialty-llc-193722","firm":"Viatris Specialty LLC","date":"2026-07-13","product":"TOBI® PODHALER® (tobramycin inhalation powder), for oral inhalation use","sourceUrl":"https://www.fda.gov/media/193722/download","publishedAt":"2026-07-13","page":1,"before":null,"paidUrl":"/untitled-letters?id=viatris-specialty-llc-193722"},{"id":"lundbeck-seattle-biopharmaceuticals-inc-193472","firm":"Lundbeck Seattle Biopharmaceuticals, Inc.","date":"2026-06-24","product":"Vyepti® (eptinezumab-jjmr) injection, for intravenous use","sourceUrl":"https://www.fda.gov/media/193472/download","publishedAt":"2026-06-24","page":1,"before":null,"paidUrl":"/untitled-letters?id=lundbeck-seattle-biopharmaceuticals-inc-193472"},{"id":"pinnacle-biologics-inc-193307","firm":"Pinnacle Biologics, Inc.","date":"2026-06-22","product":"PHOTOFRIN® (porfimer sodium) for injection, for intravenous use","sourceUrl":"https://www.fda.gov/media/193307/download","publishedAt":"2026-06-22","page":1,"before":null,"paidUrl":"/untitled-letters?id=pinnacle-biologics-inc-193307"},{"id":"qol-medical-llc-192843","firm":"QOL Medical, LLC.","date":"2026-05-26","product":"SUCRAID® (sacrosidase) oral solution","sourceUrl":"https://www.fda.gov/media/192843/download","publishedAt":"2026-05-26","page":1,"before":null,"paidUrl":"/untitled-letters?id=qol-medical-llc-192843"},{"id":"beone-medicines-usa-inc-192467","firm":"BeOne Medicines USA, Inc.","date":"2026-05-12","product":"BRUKINSA® (zanubrutinib) capsules, for oral use","sourceUrl":"https://www.fda.gov/media/192467/download","publishedAt":"2026-05-12","page":1,"before":null,"paidUrl":"/untitled-letters?id=beone-medicines-usa-inc-192467"},{"id":"bayer-healthcare-pharmaceuticals-inc-192241","firm":"Bayer HealthCare Pharmaceuticals, Inc.","date":"2026-04-28","product":"NUBEQA® (darolutamide) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/192241/download","publishedAt":"2026-04-28","page":1,"before":null,"paidUrl":"/untitled-letters?id=bayer-healthcare-pharmaceuticals-inc-192241"},{"id":"alnylam-pharmaceuticals-inc-192265","firm":"Alnylam Pharmaceuticals, Inc.","date":"2026-04-23","product":"AMVUTTRA® (vutrisiran) injection, for subcutaneous use","sourceUrl":"https://www.fda.gov/media/192265/download","publishedAt":"2026-04-23","page":1,"before":null,"paidUrl":"/untitled-letters?id=alnylam-pharmaceuticals-inc-192265"},{"id":"incyte-corporation-192125","firm":"Incyte Corporation","date":"2026-04-22","product":"NIKTIMVO™ (axatilimab-csfr) injection, for intravenous use","sourceUrl":"https://www.fda.gov/media/192125/download","publishedAt":"2026-04-22","page":1,"before":null,"paidUrl":"/untitled-letters?id=incyte-corporation-192125"},{"id":"pfizer-inc-191932","firm":"Pfizer, Inc","date":"2026-04-08","product":"ADCETRIS® (brentuximab vedotin) for injection, for intravenous use","sourceUrl":"https://www.fda.gov/media/191932/download","publishedAt":"2026-04-08","page":2,"before":"incyte-corporation-192125","paidUrl":"/untitled-letters?id=pfizer-inc-191932"},{"id":"amneal-pharmaceuticals-llc-191883","firm":"Amneal Pharmaceuticals LLC","date":"2026-03-31","product":"ALYMSYS® (bevacizumab-maly) injection, for intravenous use","sourceUrl":"https://www.fda.gov/media/191883/download","publishedAt":"2026-03-31","page":2,"before":"incyte-corporation-192125","paidUrl":"/untitled-letters?id=amneal-pharmaceuticals-llc-191883"},{"id":"biocorrx-pharmaceuticals-inc-191875","firm":"BioCorRx Pharmaceuticals Inc.","date":"2026-03-27","product":"LUCEMYRA® (lofexidine) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/191875/download","publishedAt":"2026-03-27","page":2,"before":"incyte-corporation-192125","paidUrl":"/untitled-letters?id=biocorrx-pharmaceuticals-inc-191875"},{"id":"iovance-biotherapeutics-191631","firm":"Iovance Biotherapeutics","date":"2026-03-09","product":"AMTAGVI (lifileucel)","sourceUrl":"https://www.fda.gov/media/191631/download","publishedAt":"2026-03-09","page":2,"before":"incyte-corporation-192125","paidUrl":"/untitled-letters?id=iovance-biotherapeutics-191631"},{"id":"juno-therapeutics-inc-a-bristol-myers-squibb-company-191630","firm":"Juno Therapeutics Inc., a Bristol-Myers Squibb Company","date":"2026-03-09","product":"BREYANZI (lisocabtagene maraleucel)","sourceUrl":"https://www.fda.gov/media/191630/download","publishedAt":"2026-03-09","page":2,"before":"incyte-corporation-192125","paidUrl":"/untitled-letters?id=juno-therapeutics-inc-a-bristol-myers-squibb-company-191630"},{"id":"novartis-pharmaceuticals-corporation-191632","firm":"Novartis Pharmaceuticals Corporation","date":"2026-03-09","product":"KYMRIAH (tisagenlecleucel)","sourceUrl":"https://www.fda.gov/media/191632/download","publishedAt":"2026-03-09","page":2,"before":"incyte-corporation-192125","paidUrl":"/untitled-letters?id=novartis-pharmaceuticals-corporation-191632"},{"id":"kite-pharma-inc-191633","firm":"Kite Pharma, Inc.","date":"2026-03-09","product":"TECARTUS (brexucabtagene autoleucel)","sourceUrl":"https://www.fda.gov/media/191633/download","publishedAt":"2026-03-09","page":2,"before":"incyte-corporation-192125","paidUrl":"/untitled-letters?id=kite-pharma-inc-191633"},{"id":"novo-nordisk-inc-191387","firm":"Novo Nordisk Inc.","date":"2026-02-26","product":"OZEMPIC® (semaglutide) injection, for subcutaneous use","sourceUrl":"https://www.fda.gov/media/191387/download","publishedAt":"2026-02-26","page":2,"before":"incyte-corporation-192125","paidUrl":"/untitled-letters?id=novo-nordisk-inc-191387"},{"id":"janssen-biotech-inc-191066","firm":"Janssen Biotech, Inc.","date":"2026-02-06","product":"TREMFYA® (guselkumab) injection, for subcutaneous or intravenous use","sourceUrl":"https://www.fda.gov/media/191066/download","publishedAt":"2026-02-06","page":2,"before":"incyte-corporation-192125","paidUrl":"/untitled-letters?id=janssen-biotech-inc-191066"},{"id":"sobi-inc-191036","firm":"Sobi, Inc.","date":"2026-02-06","product":"VONJO® (pacritinib) capsules, for oral use","sourceUrl":"https://www.fda.gov/media/191036/download","publishedAt":"2026-02-06","page":2,"before":"incyte-corporation-192125","paidUrl":"/untitled-letters?id=sobi-inc-191036"},{"id":"novo-nordisk-inc-191020","firm":"Novo Nordisk Inc.","date":"2026-02-05","product":"WEGOVY® (semaglutide) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/191020/download","publishedAt":"2026-02-05","page":3,"before":"sobi-inc-191036","paidUrl":"/untitled-letters?id=novo-nordisk-inc-191020"},{"id":"argenx-us-inc-191009","firm":"argenx US, Inc.","date":"2026-01-30","product":"VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) injection, for","sourceUrl":"https://www.fda.gov/media/191009/download","publishedAt":"2026-01-30","page":3,"before":"sobi-inc-191036","paidUrl":"/untitled-letters?id=argenx-us-inc-191009"},{"id":"argenx-us-inc-191010","firm":"argenx US, Inc.","date":"2026-01-30","product":"VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) injection, for","sourceUrl":"https://www.fda.gov/media/191010/download","publishedAt":"2026-01-30","page":3,"before":"sobi-inc-191036","paidUrl":"/untitled-letters?id=argenx-us-inc-191010"},{"id":"ars-pharmaceutical-operations-inc-190753","firm":"ARS Pharmaceutical Operations, Inc.","date":"2026-01-23","product":"NEFFY® (epinephrine nasal spray)","sourceUrl":"https://www.fda.gov/media/190753/download","publishedAt":"2026-01-23","page":3,"before":"sobi-inc-191036","paidUrl":"/untitled-letters?id=ars-pharmaceutical-operations-inc-190753"},{"id":"altor-bioscience-llc-an-indirect-wholly-owned-subsidiary-of-immunitybio-inc-190567","firm":"Altor BioScience, LLC, (an indirect wholly-owned subsidiary of ImmunityBio, Inc.)","date":"2026-01-07","product":"ANKTIVA® (nogapendekin alfa inbakicept-pmln) solution, for intravesical use","sourceUrl":"https://www.fda.gov/media/190567/download","publishedAt":"2026-01-07","page":3,"before":"sobi-inc-191036","paidUrl":"/untitled-letters?id=altor-bioscience-llc-an-indirect-wholly-owned-subsidiary-of-immunitybio-inc-190567"},{"id":"beone-medicines-usa-inc-190549","firm":"BeOne Medicines USA, Inc.","date":"2026-01-07","product":"BRUKINSA® (zanubrutinib) capsules, for oral use","sourceUrl":"https://www.fda.gov/media/190549/download","publishedAt":"2026-01-07","page":3,"before":"sobi-inc-191036","paidUrl":"/untitled-letters?id=beone-medicines-usa-inc-190549"},{"id":"esperion-therapeutics-inc-190458","firm":"Esperion Therapeutics, Inc.","date":"2025-12-19","product":"NOA 211617","sourceUrl":"https://www.fda.gov/media/190458/download","publishedAt":"2025-12-19","page":3,"before":"sobi-inc-191036","paidUrl":"/untitled-letters?id=esperion-therapeutics-inc-190458"},{"id":"beone-medicines-usa-inc-190494","firm":"BeOne Medicines USA, Inc.","date":"2025-12-15","product":"TEVIMBRA® (tislelizumab-jsgr) injection, for intravenous use","sourceUrl":"https://www.fda.gov/media/190494/download","publishedAt":"2025-12-15","page":3,"before":"sobi-inc-191036","paidUrl":"/untitled-letters?id=beone-medicines-usa-inc-190494"},{"id":"karuna-therapeutics-inc-a-bristol-myers-squibb-co-190245","firm":"Karuna Therapeutics, Inc., a Bristol Myers Squibb Co.","date":"2025-12-15","product":"COBENFYTM (xanomeline and trospium chloride) capsules, for oral use","sourceUrl":"https://www.fda.gov/media/190245/download","publishedAt":"2025-12-15","page":3,"before":"sobi-inc-191036","paidUrl":"/untitled-letters?id=karuna-therapeutics-inc-a-bristol-myers-squibb-co-190245"},{"id":"daiichi-sankyo-inc-189913","firm":"Daiichi Sankyo, Inc.","date":"2025-11-24","product":"TURALIO® (pexidartinib) capsules, for oral use","sourceUrl":"https://www.fda.gov/media/189913/download","publishedAt":"2025-11-24","page":3,"before":"sobi-inc-191036","paidUrl":"/untitled-letters?id=daiichi-sankyo-inc-189913"},{"id":"sk-life-science-inc-189733","firm":"SK Life Science, Inc.","date":"2025-09-30","product":"Xcopri® (cenobamate tablets) for oral use, CV","sourceUrl":"https://www.fda.gov/media/189733/download","publishedAt":"2025-09-30","page":4,"before":"daiichi-sankyo-inc-189913","paidUrl":"/untitled-letters?id=sk-life-science-inc-189733"},{"id":"pharmather-inc-189734","firm":"PharmaTher Inc.","date":"2025-09-30","product":"ANDA 217858 KETAMINE HYDROCHLORIDE injection, for intravenous or intramuscular use, CII MA 2","sourceUrl":"https://www.fda.gov/media/189734/download","publishedAt":"2025-09-30","page":4,"before":"daiichi-sankyo-inc-189913","paidUrl":"/untitled-letters?id=pharmather-inc-189734"},{"id":"astrazeneca-189634","firm":"AstraZeneca","date":"2025-09-23","product":"FARXIGA® (dapagliflozin) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/189634/download","publishedAt":"2025-09-23","page":4,"before":"daiichi-sankyo-inc-189913","paidUrl":"/untitled-letters?id=astrazeneca-189634"},{"id":"novartis-pharmaceuticals-corporation-188954","firm":"Novartis Pharmaceuticals Corporation","date":"2025-09-23","product":"FABHALTA® (iptacopan) capsules, for oral use","sourceUrl":"https://www.fda.gov/media/188954/download","publishedAt":"2025-09-23","page":4,"before":"daiichi-sankyo-inc-189913","paidUrl":"/untitled-letters?id=novartis-pharmaceuticals-corporation-188954"},{"id":"glaxosmithkline-llc-189906","firm":"GlaxoSmithKline LLC","date":"2025-09-09","product":"APRETUDE (cabotegravir extended-release injectable suspension), for intramuscular","sourceUrl":"https://www.fda.gov/media/189906/download","publishedAt":"2025-09-09","page":7,"before":"galderma-laboratories-l-p-188706","paidUrl":"/untitled-letters?id=glaxosmithkline-llc-189906"},{"id":"aadi-bioscience-188963","firm":"Aadi Bioscience","date":"2025-09-09","product":"FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-","sourceUrl":"https://www.fda.gov/media/188963/download","publishedAt":"2025-09-09","page":4,"before":"daiichi-sankyo-inc-189913","paidUrl":"/untitled-letters?id=aadi-bioscience-188963"},{"id":"altor-bioscience-llc-an-indirect-wholly-owned-subsidiary-of-immunitybio-inc-188898","firm":"Altor BioScience, LLC, (an indirect wholly-owned subsidiary of ImmunityBio, Inc.)","date":"2025-09-09","product":"ANKTIVA® (nogapendekin alfa inbakicept-pmln) solution, for intravesical use","sourceUrl":"https://www.fda.gov/media/188898/download","publishedAt":"2025-09-09","page":5,"before":"alnylam-pharmaceuticals-inc-188686","paidUrl":"/untitled-letters?id=altor-bioscience-llc-an-indirect-wholly-owned-subsidiary-of-immunitybio-inc-188898"},{"id":"takeda-pharmaceuticals-america-inc-188900","firm":"Takeda Pharmaceuticals America, Inc.","date":"2025-09-09","product":"ICLUSIG® (ponatinib) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/188900/download","publishedAt":"2025-09-09","page":8,"before":"phathom-pharmaceuticals-inc-188754","paidUrl":"/untitled-letters?id=takeda-pharmaceuticals-america-inc-188900"},{"id":"amgen-inc-188901","firm":"Amgen Inc.","date":"2025-09-09","product":"IMDELLTRA™ (tarlatamab-dlle) for injection, for intravenous use","sourceUrl":"https://www.fda.gov/media/188901/download","publishedAt":"2025-09-09","page":5,"before":"alnylam-pharmaceuticals-inc-188686","paidUrl":"/untitled-letters?id=amgen-inc-188901"},{"id":"evolus-inc-188902","firm":"Evolus, Inc.","date":"2025-09-09","product":"JEUVEAU® (prabotulinumtoxinA-xvfs) for injection, for intramuscular use","sourceUrl":"https://www.fda.gov/media/188902/download","publishedAt":"2025-09-09","page":6,"before":"azurity-pharmaceuticals-inc-188703","paidUrl":"/untitled-letters?id=evolus-inc-188902"},{"id":"incyte-corporation-188903","firm":"Incyte Corporation","date":"2025-09-09","product":"PEMAZYRE® (pemigatinib) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/188903/download","publishedAt":"2025-09-09","page":7,"before":"galderma-laboratories-l-p-188706","paidUrl":"/untitled-letters?id=incyte-corporation-188903"},{"id":"pinnacle-biologics-inc-188905","firm":"Pinnacle Biologics, Inc.","date":"2025-09-09","product":"PHOTOFRIN® (porfimer sodium) for injection, for intravenous use","sourceUrl":"https://www.fda.gov/media/188905/download","publishedAt":"2025-09-09","page":8,"before":"phathom-pharmaceuticals-inc-188754","paidUrl":"/untitled-letters?id=pinnacle-biologics-inc-188905"},{"id":"pinnacle-biologics-inc-188904","firm":"Pinnacle Biologics, Inc.","date":"2025-09-09","product":"PHOTOFRIN® (porfimer sodium) for injection, for intravenous use","sourceUrl":"https://www.fda.gov/media/188904/download","publishedAt":"2025-09-09","page":8,"before":"phathom-pharmaceuticals-inc-188754","paidUrl":"/untitled-letters?id=pinnacle-biologics-inc-188904"},{"id":"ucb-inc-188906","firm":"UCB, Inc.","date":"2025-09-09","product":"RYSTIGGO® (rozanolixizumab-noli) injection, for subcutaneous use","sourceUrl":"https://www.fda.gov/media/188906/download","publishedAt":"2025-09-09","page":9,"before":"takeda-pharmaceuticals-usa-inc-188752","paidUrl":"/untitled-letters?id=ucb-inc-188906"},{"id":"abbvie-inc-188908","firm":"AbbVie, Inc.","date":"2025-09-09","product":"5; 761262","sourceUrl":"https://www.fda.gov/media/188908/download","publishedAt":"2025-09-09","page":4,"before":"daiichi-sankyo-inc-189913","paidUrl":"/untitled-letters?id=abbvie-inc-188908"},{"id":"ipsen-biopharmaceuticals-inc-188907","firm":"Ipsen Biopharmaceuticals, Inc.","date":"2025-09-09","product":"TAZVERIK® (tazemetostat) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/188907/download","publishedAt":"2025-09-09","page":7,"before":"galderma-laboratories-l-p-188706","paidUrl":"/untitled-letters?id=ipsen-biopharmaceuticals-inc-188907"},{"id":"alnylam-pharmaceuticals-inc-188686","firm":"Alnylam Pharmaceuticals, Inc.","date":"2025-09-09","product":"AMVUTTRA® (vutrisiran) injection, for subcutaneous use","sourceUrl":"https://www.fda.gov/media/188686/download","publishedAt":"2025-09-09","page":4,"before":"daiichi-sankyo-inc-189913","paidUrl":"/untitled-letters?id=alnylam-pharmaceuticals-inc-188686"},{"id":"bridgebio-pharma-inc-188687","firm":"BridgeBio Pharma, Inc.","date":"2025-09-09","product":"ATTRUBY® (acoramidis) tablets","sourceUrl":"https://www.fda.gov/media/188687/download","publishedAt":"2025-09-09","page":6,"before":"azurity-pharmaceuticals-inc-188703","paidUrl":"/untitled-letters?id=bridgebio-pharma-inc-188687"},{"id":"teva-neuroscience-inc-188719","firm":"Teva Neuroscience, Inc.","date":"2025-09-09","product":"AUSTEDO® XR (deutetrabenazine) extended-release tablets, for oral use","sourceUrl":"https://www.fda.gov/media/188719/download","publishedAt":"2025-09-09","page":9,"before":"takeda-pharmaceuticals-usa-inc-188752","paidUrl":"/untitled-letters?id=teva-neuroscience-inc-188719"},{"id":"teva-neuroscience-inc-188720","firm":"Teva Neuroscience, Inc.","date":"2025-09-09","product":"AUSTEDO® XR (deutetrabenazine) extended-release tablets, for oral use","sourceUrl":"https://www.fda.gov/media/188720/download","publishedAt":"2025-09-09","page":9,"before":"takeda-pharmaceuticals-usa-inc-188752","paidUrl":"/untitled-letters?id=teva-neuroscience-inc-188720"},{"id":"axsome-therapeutics-inc-188689","firm":"Axsome Therapeutics, Inc.","date":"2025-09-09","product":"AUVELITY® (dextromethorphan hydrobromide and bupropion hydrochloride)","sourceUrl":"https://www.fda.gov/media/188689/download","publishedAt":"2025-09-09","page":5,"before":"alnylam-pharmaceuticals-inc-188686","paidUrl":"/untitled-letters?id=axsome-therapeutics-inc-188689"},{"id":"ucb-inc-188691","firm":"UCB, Inc.","date":"2025-09-09","product":"BIMZELX® (bimekizumab-bkzx) injection, for subcutaneous use","sourceUrl":"https://www.fda.gov/media/188691/download","publishedAt":"2025-09-09","page":9,"before":"takeda-pharmaceuticals-usa-inc-188752","paidUrl":"/untitled-letters?id=ucb-inc-188691"},{"id":"ucb-inc-188693","firm":"UCB, Inc.","date":"2025-09-09","product":"BIMZELX® (bimekizumab-bkzx) injection, for subcutaneous use","sourceUrl":"https://www.fda.gov/media/188693/download","publishedAt":"2025-09-09","page":9,"before":"takeda-pharmaceuticals-usa-inc-188752","paidUrl":"/untitled-letters?id=ucb-inc-188693"},{"id":"ucb-inc-188695","firm":"UCB, Inc.","date":"2025-09-09","product":"BIMZELX® (bimekizumab-bkzx) injection, for subcutaneous use","sourceUrl":"https://www.fda.gov/media/188695/download","publishedAt":"2025-09-09","page":9,"before":"takeda-pharmaceuticals-usa-inc-188752","paidUrl":"/untitled-letters?id=ucb-inc-188695"},{"id":"astrazeneca-pharmaceuticals-lp-188697","firm":"AstraZeneca Pharmaceuticals LP","date":"2025-09-09","product":"CALQUENCE® (acalabrutinib) capsules, for oral use","sourceUrl":"https://www.fda.gov/media/188697/download","publishedAt":"2025-09-09","page":5,"before":"alnylam-pharmaceuticals-inc-188686","paidUrl":"/untitled-letters?id=astrazeneca-pharmaceuticals-lp-188697"},{"id":"bristol-myers-squibb-188699","firm":"Bristol Myers Squibb","date":"2025-09-09","product":"CAMZYOS® (mavacamten) capsules for oral use","sourceUrl":"https://www.fda.gov/media/188699/download","publishedAt":"2025-09-09","page":6,"before":"azurity-pharmaceuticals-inc-188703","paidUrl":"/untitled-letters?id=bristol-myers-squibb-188699"},{"id":"nalpropion-pharmaceuticals-llc-188701","firm":"Nalpropion Pharmaceuticals, LLC","date":"2025-09-09","product":"CONTRAVE (naltrexone hydrochloride and bupropion hydrochloride) extended-","sourceUrl":"https://www.fda.gov/media/188701/download","publishedAt":"2025-09-09","page":7,"before":"galderma-laboratories-l-p-188706","paidUrl":"/untitled-letters?id=nalpropion-pharmaceuticals-llc-188701"},{"id":"azurity-pharmaceuticals-inc-188703","firm":"Azurity Pharmaceuticals, Inc.","date":"2025-09-09","product":"DANZITEN (nilotinib) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/188703/download","publishedAt":"2025-09-09","page":5,"before":"alnylam-pharmaceuticals-inc-188686","paidUrl":"/untitled-letters?id=azurity-pharmaceuticals-inc-188703"},{"id":"astrazeneca-pharmaceuticals-lp-188717","firm":"AstraZeneca Pharmaceuticals LP","date":"2025-09-09","product":"FASENRA® (benralizumab) injection, for subcutaneous use","sourceUrl":"https://www.fda.gov/media/188717/download","publishedAt":"2025-09-09","page":5,"before":"alnylam-pharmaceuticals-inc-188686","paidUrl":"/untitled-letters?id=astrazeneca-pharmaceuticals-lp-188717"},{"id":"astrazeneca-pharmaceuticals-lp-188732","firm":"AstraZeneca Pharmaceuticals LP","date":"2025-09-09","product":"FASENRA® (benralizumab) injection, for subcutaneous use","sourceUrl":"https://www.fda.gov/media/188732/download","publishedAt":"2025-09-09","page":5,"before":"alnylam-pharmaceuticals-inc-188686","paidUrl":"/untitled-letters?id=astrazeneca-pharmaceuticals-lp-188732"},{"id":"astrazeneca-pharmaceuticals-lp-188733","firm":"AstraZeneca Pharmaceuticals LP","date":"2025-09-09","product":"FASENRA® (benralizumab) injection, for subcutaneous use","sourceUrl":"https://www.fda.gov/media/188733/download","publishedAt":"2025-09-09","page":5,"before":"alnylam-pharmaceuticals-inc-188686","paidUrl":"/untitled-letters?id=astrazeneca-pharmaceuticals-lp-188733"},{"id":"takeda-pharmaceuticals-usa-inc-188752","firm":"Takeda Pharmaceuticals USA, Inc.","date":"2025-09-09","product":"FRUZAQLA® (fruquintinib) capsules, for oral use","sourceUrl":"https://www.fda.gov/media/188752/download","publishedAt":"2025-09-09","page":8,"before":"phathom-pharmaceuticals-inc-188754","paidUrl":"/untitled-letters?id=takeda-pharmaceuticals-usa-inc-188752"},{"id":"takeda-pharmaceuticals-usa-inc-188744","firm":"Takeda Pharmaceuticals USA, Inc.","date":"2025-09-09","product":"FRUZAQLA™ (fruquintinib) capsules, for oral use","sourceUrl":"https://www.fda.gov/media/188744/download","publishedAt":"2025-09-09","page":8,"before":"phathom-pharmaceuticals-inc-188754","paidUrl":"/untitled-letters?id=takeda-pharmaceuticals-usa-inc-188744"},{"id":"neurocrine-biosciences-inc-188721","firm":"Neurocrine Biosciences, Inc","date":"2025-09-09","product":"INGREZZA® (valbenazine) capsules, for oral use","sourceUrl":"https://www.fda.gov/media/188721/download","publishedAt":"2025-09-09","page":7,"before":"galderma-laboratories-l-p-188706","paidUrl":"/untitled-letters?id=neurocrine-biosciences-inc-188721"},{"id":"novartis-pharmaceuticals-corporation-188723","firm":"Novartis Pharmaceuticals Corporation","date":"2025-09-09","product":"Kesimpta® (ofatumumab) infection, for subcutaneous use","sourceUrl":"https://www.fda.gov/media/188723/download","publishedAt":"2025-09-09","page":7,"before":"galderma-laboratories-l-p-188706","paidUrl":"/untitled-letters?id=novartis-pharmaceuticals-corporation-188723"},{"id":"boehringer-ingelheim-pharmaceuticals-inc-188746","firm":"Boehringer Ingelheim Pharmaceuticals, Inc.","date":"2025-09-09","product":"JARDIANCE® (empagliflozin tablets), for oral use","sourceUrl":"https://www.fda.gov/media/188746/download","publishedAt":"2025-09-09","page":6,"before":"azurity-pharmaceuticals-inc-188703","paidUrl":"/untitled-letters?id=boehringer-ingelheim-pharmaceuticals-inc-188746"},{"id":"boehringer-ingelheim-pharmaceuticals-inc-188747","firm":"Boehringer Ingelheim Pharmaceuticals, Inc.","date":"2025-09-09","product":"JARDIANCE® (empagliflozin tablets), for oral use","sourceUrl":"https://www.fda.gov/media/188747/download","publishedAt":"2025-09-09","page":6,"before":"azurity-pharmaceuticals-inc-188703","paidUrl":"/untitled-letters?id=boehringer-ingelheim-pharmaceuticals-inc-188747"},{"id":"boehringer-ingelheim-pharmaceuticals-inc-188748","firm":"Boehringer Ingelheim Pharmaceuticals, Inc.","date":"2025-09-09","product":"JARDIANCE® (empagliflozin tablets), for oral use","sourceUrl":"https://www.fda.gov/media/188748/download","publishedAt":"2025-09-09","page":6,"before":"azurity-pharmaceuticals-inc-188703","paidUrl":"/untitled-letters?id=boehringer-ingelheim-pharmaceuticals-inc-188748"},{"id":"bausch-health-companies-inc-188749","firm":"Bausch Health Companies Inc.","date":"2025-09-09","product":"JUBLIA® (efinaconazole) topical solution, 10% for topical use","sourceUrl":"https://www.fda.gov/media/188749/download","publishedAt":"2025-09-09","page":6,"before":"azurity-pharmaceuticals-inc-188703","paidUrl":"/untitled-letters?id=bausch-health-companies-inc-188749"},{"id":"novartis-pharmaceuticals-corporation-188751","firm":"Novartis Pharmaceuticals Corporation","date":"2025-09-09","product":"KISQALI® (ribociclib) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/188751/download","publishedAt":"2025-09-09","page":7,"before":"galderma-laboratories-l-p-188706","paidUrl":"/untitled-letters?id=novartis-pharmaceuticals-corporation-188751"},{"id":"abbvie-inc-188750","firm":"AbbVie, Inc.","date":"2025-09-09","product":"LINZESS® (linaclotide) capsules, for oral use","sourceUrl":"https://www.fda.gov/media/188750/download","publishedAt":"2025-09-09","page":4,"before":"daiichi-sankyo-inc-189913","paidUrl":"/untitled-letters?id=abbvie-inc-188750"},{"id":"ars-pharmaceutical-operations-inc-188705","firm":"ARS Pharmaceutical Operations, Inc.","date":"2025-09-09","product":"NEFFY® (epinephrine nasal spray)","sourceUrl":"https://www.fda.gov/media/188705/download","publishedAt":"2025-09-09","page":5,"before":"alnylam-pharmaceuticals-inc-188686","paidUrl":"/untitled-letters?id=ars-pharmaceutical-operations-inc-188705"},{"id":"galderma-laboratories-l-p-188706","firm":"Galderma Laboratories, L.P.","date":"2025-09-09","product":"NEMLUVIO® (nemolizumab-ilto) for injection, for subcutaneous use","sourceUrl":"https://www.fda.gov/media/188706/download","publishedAt":"2025-09-09","page":6,"before":"azurity-pharmaceuticals-inc-188703","paidUrl":"/untitled-letters?id=galderma-laboratories-l-p-188706"},{"id":"bristol-myers-squibb-188707","firm":"Bristol-Myers Squibb","date":"2025-09-09","product":"OPDIVO QVANTIG™ (nivolumab and hyaluronidase-nvhy) injection, for subcutaneous","sourceUrl":"https://www.fda.gov/media/188707/download","publishedAt":"2025-09-09","page":6,"before":"azurity-pharmaceuticals-inc-188703","paidUrl":"/untitled-letters?id=bristol-myers-squibb-188707"},{"id":"bristol-myers-squibb-188708","firm":"Bristol-Myers Squibb","date":"2025-09-09","product":"OPDIVO® (nivolumab) injection, for intravenous use","sourceUrl":"https://www.fda.gov/media/188708/download","publishedAt":"2025-09-09","page":6,"before":"azurity-pharmaceuticals-inc-188703","paidUrl":"/untitled-letters?id=bristol-myers-squibb-188708"},{"id":"supernus-pharmaceuticals-inc-188725","firm":"Supernus Pharmaceuticals, Inc.","date":"2025-09-09","product":"QELBREE® (viloxazine extended-release capsules), for oral use","sourceUrl":"https://www.fda.gov/media/188725/download","publishedAt":"2025-09-09","page":8,"before":"phathom-pharmaceuticals-inc-188754","paidUrl":"/untitled-letters?id=supernus-pharmaceuticals-inc-188725"},{"id":"supernus-pharmaceuticals-inc-188727","firm":"Supernus Pharmaceuticals, Inc.","date":"2025-09-09","product":"QELBREE® (viloxazine extended-release capsules), for oral use","sourceUrl":"https://www.fda.gov/media/188727/download","publishedAt":"2025-09-09","page":8,"before":"phathom-pharmaceuticals-inc-188754","paidUrl":"/untitled-letters?id=supernus-pharmaceuticals-inc-188727"},{"id":"abbvie-inc-188729","firm":"AbbVie, Inc.","date":"2025-09-09","product":"Qulipta® (atogepant) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/188729/download","publishedAt":"2025-09-09","page":4,"before":"daiichi-sankyo-inc-189913","paidUrl":"/untitled-letters?id=abbvie-inc-188729"},{"id":"novartis-pharmaceuticals-corporation-188710","firm":"Novartis Pharmaceuticals Corporation","date":"2025-09-09","product":"PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use","sourceUrl":"https://www.fda.gov/media/188710/download","publishedAt":"2025-09-09","page":7,"before":"galderma-laboratories-l-p-188706","paidUrl":"/untitled-letters?id=novartis-pharmaceuticals-corporation-188710"},{"id":"astrazeneca-pharmaceuticals-lp-188712","firm":"AstraZeneca Pharmaceuticals LP","date":"2025-09-09","product":"TRUQAP® (capivasertib) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/188712/download","publishedAt":"2025-09-09","page":5,"before":"alnylam-pharmaceuticals-inc-188686","paidUrl":"/untitled-letters?id=astrazeneca-pharmaceuticals-lp-188712"},{"id":"sanofi-188713","firm":"Sanofi","date":"2025-09-09","product":"TZIELD® (teplizumab-mzwv) injection, for intravenous use","sourceUrl":"https://www.fda.gov/media/188713/download","publishedAt":"2025-09-09","page":8,"before":"phathom-pharmaceuticals-inc-188754","paidUrl":"/untitled-letters?id=sanofi-188713"},{"id":"pfizer-inc-188715","firm":"Pfizer, Inc.","date":"2025-09-09","product":"VELSIPITY™ (etrasimod) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/188715/download","publishedAt":"2025-09-09","page":7,"before":"galderma-laboratories-l-p-188706","paidUrl":"/untitled-letters?id=pfizer-inc-188715"},{"id":"phathom-pharmaceuticals-inc-188755","firm":"Phathom Pharmaceuticals, Inc.","date":"2025-09-09","product":"VOQUEZNA (vonoprazan) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/188755/download","publishedAt":"2025-09-09","page":8,"before":"phathom-pharmaceuticals-inc-188754","paidUrl":"/untitled-letters?id=phathom-pharmaceuticals-inc-188755"},{"id":"phathom-pharmaceuticals-inc-188754","firm":"Phathom Pharmaceuticals, Inc.","date":"2025-09-09","product":"VOQUEZNA (vonoprazan) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/188754/download","publishedAt":"2025-09-09","page":7,"before":"galderma-laboratories-l-p-188706","paidUrl":"/untitled-letters?id=phathom-pharmaceuticals-inc-188754"},{"id":"phathom-pharmaceuticals-inc-188756","firm":"Phathom Pharmaceuticals, Inc.","date":"2025-09-09","product":"VOQUEZNA (vonoprazan) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/188756/download","publishedAt":"2025-09-09","page":8,"before":"phathom-pharmaceuticals-inc-188754","paidUrl":"/untitled-letters?id=phathom-pharmaceuticals-inc-188756"},{"id":"alexion-pharmaceuticals-inc-188731","firm":"Alexion Pharmaceuticals, Inc.","date":"2025-09-09","product":"ULTOMIRIS® (ravulizumab-cwvz) injection, for intravenous use","sourceUrl":"https://www.fda.gov/media/188731/download","publishedAt":"2025-09-09","page":4,"before":"daiichi-sankyo-inc-189913","paidUrl":"/untitled-letters?id=alexion-pharmaceuticals-inc-188731"},{"id":"mayne-pharma-llc-186470","firm":"Mayne Pharma LLC","date":"2025-04-28","product":"NEXTSTELLIS (drospirenone and estetrol tablets), for oral use","sourceUrl":"https://www.fda.gov/media/186470/download","publishedAt":"2025-04-28","page":9,"before":"takeda-pharmaceuticals-usa-inc-188752","paidUrl":"/untitled-letters?id=mayne-pharma-llc-186470"},{"id":"taiho-oncology-inc-185959","firm":"Taiho Oncology, Inc.","date":"2025-03-21","product":"LYTGOBI® (futibatinib) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/185959/download","publishedAt":"2025-03-21","page":9,"before":"takeda-pharmaceuticals-usa-inc-188752","paidUrl":"/untitled-letters?id=taiho-oncology-inc-185959"},{"id":"edenbridge-dba-dexcel-185653","firm":"Edenbridge DBA Dexcel","date":"2025-02-03","product":"HEMADY (dexamethasone tablets), for oral use","sourceUrl":"https://www.fda.gov/media/185653/download","publishedAt":"2025-02-03","page":9,"before":"takeda-pharmaceuticals-usa-inc-188752","paidUrl":"/untitled-letters?id=edenbridge-dba-dexcel-185653"},{"id":"merz-pharmaceuticals-gmbh-183512","firm":"Merz Pharmaceuticals GmbH","date":"2024-10-31","product":"360","sourceUrl":"https://www.fda.gov/media/183512/download","publishedAt":"2024-10-31","page":9,"before":"takeda-pharmaceuticals-usa-inc-188752","paidUrl":"/untitled-letters?id=merz-pharmaceuticals-gmbh-183512"},{"id":"abbvie-inc-181754","firm":"AbbVie, Inc.","date":"2024-08-29","product":"UBRELVY (ubrogepant) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/181754/download","publishedAt":"2024-08-29","page":10,"before":"merz-pharmaceuticals-gmbh-183512","paidUrl":"/untitled-letters?id=abbvie-inc-181754"},{"id":"mirati-therapeutics-inc-a-bristol-myers-squibb-co-180633","firm":"Mirati Therapeutics Inc., a Bristol Myers Squibb Co.","date":"2024-08-01","product":"KRAZATI™ (adagrasib) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/180633/download","publishedAt":"2024-08-01","page":10,"before":"merz-pharmaceuticals-gmbh-183512","paidUrl":"/untitled-letters?id=mirati-therapeutics-inc-a-bristol-myers-squibb-co-180633"},{"id":"kaleo-inc-180350","firm":"Kaleo, Inc.","date":"2024-07-17","product":"AUVI-Q® (epinephrine injection, USP), for intramuscular or subcutaneous use","sourceUrl":"https://www.fda.gov/media/180350/download","publishedAt":"2024-07-17","page":10,"before":"merz-pharmaceuticals-gmbh-183512","paidUrl":"/untitled-letters?id=kaleo-inc-180350"},{"id":"novartis-pharmaceuticals-corporation-175584","firm":"Novartis Pharmaceuticals Corporation","date":"2024-01-18","product":"NDA 209092","sourceUrl":"https://www.fda.gov/media/175584/download","publishedAt":"2024-01-18","page":10,"before":"merz-pharmaceuticals-gmbh-183512","paidUrl":"/untitled-letters?id=novartis-pharmaceuticals-corporation-175584"},{"id":"otsuka-pharmaceutical-development-and-commercialization-inc-173730","firm":"Otsuka Pharmaceutical Development and Commercialization, Inc","date":"2023-10-31","product":"REXULTI® (brexpiprazole) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/173730/download","publishedAt":"2023-10-31","page":10,"before":"merz-pharmaceuticals-gmbh-183512","paidUrl":"/untitled-letters?id=otsuka-pharmaceutical-development-and-commercialization-inc-173730"},{"id":"evofem-biosciences-173696","firm":"Evofem Biosciences","date":"2023-10-31","product":"NDA 208352 PHEXXI (lactic acid, citric acid, and potassium bitartrate) vaginal gel","sourceUrl":"https://www.fda.gov/media/173696/download","publishedAt":"2023-10-31","page":10,"before":"merz-pharmaceuticals-gmbh-183512","paidUrl":"/untitled-letters?id=evofem-biosciences-173696"},{"id":"exeltis-usa-inc-171460","firm":"Exeltis USA Inc.","date":"2023-08-11","product":"SLYND (drospirenone) tablets, for oral use","sourceUrl":"https://www.fda.gov/media/171460/download","publishedAt":"2023-08-11","page":10,"before":"merz-pharmaceuticals-gmbh-183512","paidUrl":"/untitled-letters?id=exeltis-usa-inc-171460"},{"id":"xeris-pharmaceuticals-inc-169419","firm":"Xeris Pharmaceuticals, Inc.","date":"2023-06-07","product":"RECORLEV (levoketoconazole) tablets, oral","sourceUrl":"https://www.fda.gov/media/169419/download","publishedAt":"2023-06-07","page":10,"before":"merz-pharmaceuticals-gmbh-183512","paidUrl":"/untitled-letters?id=xeris-pharmaceuticals-inc-169419"},{"id":"althera-pharmaceuticals-158997","firm":"Althera Pharmaceuticals","date":"2022-06-02","product":"NDA 213072 ROSZET (rosuvastatin ezetimibe) tables, for oral use","sourceUrl":"https://www.fda.gov/media/158997/download","publishedAt":"2022-06-02","page":10,"before":"merz-pharmaceuticals-gmbh-183512","paidUrl":"/untitled-letters?id=althera-pharmaceuticals-158997"},{"id":"bausch-health-companies-inc-159926","firm":"Bausch Health Companies Inc","date":"2022-03-31","product":"DUOBRII™ (halobetasol propionate and tazarotene) lotion, for topical use","sourceUrl":"https://www.fda.gov/media/159926/download","publishedAt":"2022-03-31","page":10,"before":"merz-pharmaceuticals-gmbh-183512","paidUrl":"/untitled-letters?id=bausch-health-companies-inc-159926"},{"id":"eli-lilly-company-155627","firm":"Eli Lilly & Company","date":"2022-01-19","product":"TRULICITY® (dulaglutide) injection, for subcutaneous use","sourceUrl":"https://www.fda.gov/media/155627/download","publishedAt":"2022-01-19","page":11,"before":"bausch-health-companies-inc-159926","paidUrl":"/untitled-letters?id=eli-lilly-company-155627"},{"id":"emgality-155419","firm":"Emgality","date":"2021-12-13","product":"EMGALITY (galcanezumab-gnlm) injection, for subcutaneous use","sourceUrl":"https://www.fda.gov/media/155419/download","publishedAt":"2021-12-13","page":11,"before":"bausch-health-companies-inc-159926","paidUrl":"/untitled-letters?id=emgality-155419"},{"id":"alkindi-sprinkle-151527","firm":"Alkindi Sprinkle","date":"2021-08-09","product":"ALKINDI® SPRINKLE (hydrocortisone) oral granules","sourceUrl":"https://www.fda.gov/media/151527/download","publishedAt":"2021-08-09","page":11,"before":"bausch-health-companies-inc-159926","paidUrl":"/untitled-letters?id=alkindi-sprinkle-151527"},{"id":"amgen-150751","firm":"Amgen","date":"2021-07-07","product":"NEULASTA® (pegfilgrastim) injection, for subcutaneous use","sourceUrl":"https://www.fda.gov/media/150751/download","publishedAt":"2021-07-07","page":11,"before":"bausch-health-companies-inc-159926","paidUrl":"/untitled-letters?id=amgen-150751"},{"id":"biohaven-pharmaceuticals-146528","firm":"Biohaven Pharmaceuticals","date":"2021-03-08","product":"NURTEC ODT (rimegepant) orally disintegrating tablets, for sublingual or oral use","sourceUrl":"https://www.fda.gov/media/146528/download","publishedAt":"2021-03-08","page":11,"before":"bausch-health-companies-inc-159926","paidUrl":"/untitled-letters?id=biohaven-pharmaceuticals-146528"},{"id":"azurity-pharmaceuticals-inc-144115","firm":"Azurity Pharmaceuticals Inc.","date":"2020-11-24","product":"XATMEP® (methotrexate) oral solution","sourceUrl":"https://www.fda.gov/media/144115/download","publishedAt":"2020-11-24","page":11,"before":"bausch-health-companies-inc-159926","paidUrl":"/untitled-letters?id=azurity-pharmaceuticals-inc-144115"},{"id":"xeris-pharmaceuticals-inc-141347","firm":"Xeris Pharmaceuticals, Inc.","date":"2020-08-14","product":"GVOKETM (glucagon) injection, for subcutaneous use","sourceUrl":"https://www.fda.gov/media/141347/download","publishedAt":"2020-08-14","page":11,"before":"bausch-health-companies-inc-159926","paidUrl":"/untitled-letters?id=xeris-pharmaceuticals-inc-141347"},{"id":"rockwell-medical-inc-133021","firm":"Rockwell Medical, Inc","date":"2019-11-18","product":"NDA 206317; NDA 208551","sourceUrl":"https://www.fda.gov/media/133021/download","publishedAt":"2019-11-18","page":11,"before":"bausch-health-companies-inc-159926","paidUrl":"/untitled-letters?id=rockwell-medical-inc-133021"},{"id":"nascent-biotech-inc-132641","firm":"Nascent Biotech, Inc.","date":"2019-11-01","product":"Pritumumab","sourceUrl":"https://www.fda.gov/media/132641/download","publishedAt":"2019-11-01","page":11,"before":"bausch-health-companies-inc-159926","paidUrl":"/untitled-letters?id=nascent-biotech-inc-132641"},{"id":"coopersurgical-inc-129526","firm":"CooperSurgical, Inc.","date":"2019-07-25","product":"ParaGard® T380A INTRAUTERINE COPPER CONTRACEPTIVE","sourceUrl":"https://www.fda.gov/media/129526/download","publishedAt":"2019-07-25","page":11,"before":"bausch-health-companies-inc-159926","paidUrl":"/untitled-letters?id=coopersurgical-inc-129526"},{"id":"aclaris-therapeutics-inc-128151","firm":"Aclaris Therapeutics, Inc.","date":"2019-06-14","product":"ESKATA® (hydrogen peroxide) topical solution","sourceUrl":"https://www.fda.gov/media/128151/download","publishedAt":"2019-06-14","page":12,"before":"coopersurgical-inc-129526","paidUrl":"/untitled-letters?id=aclaris-therapeutics-inc-128151"},{"id":"vivus-inc-126604","firm":"VIVUS, Inc.","date":"2019-05-22","product":"QSYMIA (phentermine and topiramate extended-release) capsules, for oral use, CIV","sourceUrl":"https://www.fda.gov/media/126604/download","publishedAt":"2019-05-22","page":12,"before":"coopersurgical-inc-129526","paidUrl":"/untitled-letters?id=vivus-inc-126604"},{"id":"phoenix-molecular-imaging-center-120674","firm":"Phoenix Molecular Imaging Center","date":"2019-02-15","product":"Sodium Acetate (C-11)","sourceUrl":"https://www.fda.gov/media/120674/download","publishedAt":"2019-02-15","page":12,"before":"coopersurgical-inc-129526","paidUrl":"/untitled-letters?id=phoenix-molecular-imaging-center-120674"},{"id":"eisai-inc-117097","firm":"Eisai Inc.","date":"2018-10-11","product":"NDA 202834; 208277","sourceUrl":"https://www.fda.gov/media/117097/download","publishedAt":"2018-10-11","page":12,"before":"coopersurgical-inc-129526","paidUrl":"/untitled-letters?id=eisai-inc-117097"},{"id":"ascend-therapeutics-us-llc-114329","firm":"ASCEND Therapeutics US, LLC","date":"2018-08-16","product":"EstroGel® 0.06% (estradiol gel) for topical use","sourceUrl":"https://www.fda.gov/media/114329/download","publishedAt":"2018-08-16","page":12,"before":"coopersurgical-inc-129526","paidUrl":"/untitled-letters?id=ascend-therapeutics-us-llc-114329"},{"id":"arog-pharmaceuticals-inc-114446","firm":"Arog Pharmaceuticals, Inc.","date":"2018-06-28","product":"Crenolanib besylate","sourceUrl":"https://www.fda.gov/media/114446/download","publishedAt":"2018-06-28","page":12,"before":"coopersurgical-inc-129526","paidUrl":"/untitled-letters?id=arog-pharmaceuticals-inc-114446"},{"id":"pfizer-inc-130321","firm":"Pfizer Inc.","date":"2018-06-19","product":"ESTRING® (estradiol vaginal ring)","sourceUrl":"https://www.fda.gov/media/130321/download","publishedAt":"2018-06-19","page":12,"before":"coopersurgical-inc-129526","paidUrl":"/untitled-letters?id=pfizer-inc-130321"},{"id":"csl-behring-llc-111817","firm":"CSL Behring LLC","date":"2018-02-27","product":"IDELVION (Coagulation Factor IX (Recombinant), Albumin Fusion","sourceUrl":"https://www.fda.gov/media/111817/download","publishedAt":"2018-02-27","page":12,"before":"coopersurgical-inc-129526","paidUrl":"/untitled-letters?id=csl-behring-llc-111817"},{"id":"collegium-pharmaceuticals-inc-111101","firm":"Collegium Pharmaceuticals, Inc.","date":"2018-02-09","product":"XTAMPZA ER™ (oxycodone) extended-release capsules, for oral use, CII","sourceUrl":"https://www.fda.gov/media/111101/download","publishedAt":"2018-02-09","page":12,"before":"coopersurgical-inc-129526","paidUrl":"/untitled-letters?id=collegium-pharmaceuticals-inc-111101"},{"id":"university-of-california-los-angeles-ucla-110684","firm":"University of California Los Angeles (UCLA)","date":"2017-12-28","product":"Gallium 68 (68GA-PSMA) (Prostate Cancer Imaging webpage and brochure)","sourceUrl":"https://www.fda.gov/media/110684/download","publishedAt":"2017-12-28","page":12,"before":"coopersurgical-inc-129526","paidUrl":"/untitled-letters?id=university-of-california-los-angeles-ucla-110684"}],"schema":{"fields":["id","firm","date","product","sourceUrl"]},"sources":{"cder":"https://www.fda.gov/drugs/warning-letters-and-notice-violation-letters-pharmaceutical-companies/untitled-letters","cber":"https://www.fda.gov/vaccines-blood-biologics/enforcement-actions-cber/untitled-letters-regarding-advertising-promotional-labeling-approved-biologics","hub":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/issuance-untitled-letters","mediaBase":"https://www.fda.gov/media/"},"search":null,"before":null,"date":null,"openapi":"https://ticks.bnm.farm/openapi.json","wellKnown":"https://ticks.bnm.farm/.well-known/x402","llmsTxt":"https://ticks.bnm.farm/llms.txt","mcp":"https://ticks.bnm.farm/mcp","sample":"https://ticks.bnm.farm/sample","firmCheck":"https://ticks.bnm.farm/firm-check"}